Enovis, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham reiterated a Buy rating on the stock and has a $49.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Matson has given his Buy rating due to a combination of factors that highlight Enovis’s strong financial performance and growth potential. The company reported better-than-expected results in revenue, EBITDA, and EPS for the third quarter of 2025, surpassing market consensus. Despite a reduction in revenue guidance for 2025 due to the divestiture of Dr. Comfort, Enovis demonstrated robust organic revenue growth, with notable increases in both its Reconstructive and Prevention & Recovery segments.
Additionally, Enovis improved its free cash flow, generating $30 million in the third quarter. While there was a slight decrease in the adjusted EBITDA margin, primarily due to tariffs, the company’s adjusted gross margin showed a positive year-over-year increase. Matson views Enovis as an attractive growth at a reasonable price (GARP) investment opportunity, supported by its low price-to-earnings multiple, which further justifies the Buy rating.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENOV in relation to earlier this year.